INTRODUCTION
Lung cancer is the leading cause of cancer-related death worldwide with an alarmingly low 5-year survival rate of <15%. Therapies targeting specific genetic lesions in the tumor are increasingly being used to treat lung cancer, highlighting the need to accurately classify lung tumors based on their molecular-genetic composition. 1 Similar to somatic mutations, epigenetic modifications may provide a substrate for clonal selection during malignant transformation. As such, genome-wide methylation profiling studies can identify signatures that contribute to the molecular sub-classification of various cancers. 2 For instance, methylation profiling classifies breast tumors into its four established expression subtypes and already identified an additional subtype associated with T-lymphocyte infiltration and favorable outcome. 3 Over 50% of lung cancer patients also suffer from chronic obstructive pulmonary disease (COPD) due to shared risk factors, such as age and cigarette smoking. 4 However, COPD also independently increases the risk for lung cancer up to fivefold. 5 Although genetic association studies revealed susceptibility variants overlapping between both diseases, 6 ,7 the precise mechanisms underlying this link are incompletely understood. 8 Here, we hypothesize that the inflammatory microenvironment in COPD lungs, which results from a maladaptive response of the immune system to inhaled noxious particles, may influence lung cancer development through its impact on the epigenome. Indeed, amongst various biological processes, changes in immune response-related genes were recently observed in peripheral blood leucocytes and bronchial small airway epithelial cells of cancer-free smokers with COPD. 9 Likewise, age-related CpG island hypermethylation in non-malignant human tissues and gene-specific hypomethylation in blood of active smokers have been
10 Surprisingly, although lung cancer-specific methylation profiles have previously been generated, the potential contributions of COPD, age and smoking history to these signatures have not been assessed.
METHODS
Additional details can be found in the online supplement.
Study participants
We prospectively recruited untreated NSCLC patients scheduled for curative-intent surgery and a smoking history of 15 pack-years at the Leuven University Hospital 12 Emphysema was semi-quantitatively assessed by a radiologist, as described previously. 6, 7 Other respiratory diseases affecting pulmonary function were excluded. Previous treatments for COPD were retrieved from electronic medical files. The study protocol was approved by the local ethical committee. All participants provided written informed consent.
! *! and 1, was calculated according to the fluorescent intensity ratio.
RNA extraction and transcriptome sequencing
Total RNA was extracted from all tumor samples undergoing methylation profiling.
RNA sequencing was performed using Illumina HiSeq2000. In addition, RNA sequencing data of tumor and adjacent lung tissue samples of 178 NSCLC patients were downloaded from the TCGA portal (https://tcga-data.nci.nih.gov/tcga/).
Histological analyses
An experienced pathologist blinded to the clinical data semi-quantitatively scored 
Statistical analyses
Methylation analyses were performed on normalized "-values. Top-down unsupervised hierarchical clustering was performed using a recursively partitioned mixture model (RPMM). 13 Multivariate logistic regression models with forward stepwise selection assessed age, histological subtype, pack-years smoked, years-quit smoking, COPD status, emphysema, COPD treatment and batch as independent predictors. Differential methylation was assessed between tumor and adjacent lung tissue in the entire study population, in COPD and non-COPD subgroups. We used a Gene ontology (GO) enrichment analysis was performed using GOrilla. Only GOterms with a FDR<0.05 were considered as significantly enriched. The association of COPD with the number of tumor-infiltrating immune cells was assessed by linear regression adjusted for covariates. Statistical analyses were performed using SPSS software (v19.0) and R (v2.14.1).
RESULTS

Novel NSCLC subtypes based on DNA methylation profiling
We included 49 NSCLC patients that underwent curative-intent surgery. Tissue pairs from 3 patients were excluded due to low signal intensities for some methylation probes, as described in the online supplement. which is in accordance with the less-pronounced differences in methylation-based clusters in adjacent lung tissue. Hence, hypermethylation of immune response genes in COPD patients specifically affects the tumor tissue.
In a next step, we assessed whether the immune signature in COPD tumor tissue was attributable to a difference in the amount of immune cells infiltrating the tumor or to differential methylation of immune-related genes expressed by tumor cells. We found evidence for both mechanisms. In particular, using the Immunological Genome Project database, 17 we found that genes specifically 
Validation of an immune-specific signature in lung cancer patients with COPD
As an independent validation of the COPD-specific expression signature, we used TCGA expression data of 178 NSCLC patients for whom spirometry data were figure 3C,D) .
Finally, we also assessed which immune genes were downregulated in tumor versus adjacent tissue from COPD patients both in our discovery and validation cohort (FDR<0.05 in both cohorts). Remarkably, of the 535 genes that were significantly downregulated in COPD tumors in both cohorts, 161 genes were associated with an immune-related GO term (online supplementary table S1).
Interestingly, of the 311 genes that were both hypermethylated and downregulated in 
Histopathology of immune cell infiltrates in COPD versus non-COPD tumors
We also quantified infiltrating immune cells using histopathology. 
DISCUSSION
We studied 49 pairs of surgically-resected tumors and adjacent tissues using genome- 
